Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
OptiNose
Pharma
Paratek buys Optinose, rhinosinusitis spray Xhance for up to $330M
In a move to expand its portfolio beyond antibiotics, Paratek has bought out Optinose and its chronic rhinosinusitis nasal spray Xhance for $330M.
Kevin Dunleavy
Mar 20, 2025 11:23am
Optinose delivery system hits primary goals in sinusitis phase 3
Mar 8, 2022 8:00am
OptiNose's Xhance could zoom past predictions to blockbuster land
Apr 11, 2018 10:25am
OptiNose preps novel nasal-spray gadget for possible 2017 rollout
Oct 31, 2016 5:36pm
